Several factors that predict the outcome of large B-cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T-cell therapy can be identified before cell administration. In Onkológia. ISSN 1336-8176. Bratislava : SOLEN, 2024, 2024, roč. 19, č. 4, s. 318-319.